Literature DB >> 28762283

The risk of biochemical recurrence for intermediate-risk prostate cancer after radical prostatectomy.

Sorel Kurbegovic1, Kasper Drimer Berg1, Frederik Birkebæk Thomsen1, Lisa Gruschy1, Peter Iversen1, Klaus Brasso1, Martin Andreas Røder1.   

Abstract

OBJECTIVES: To report oncological outcomes including biochemical recurrence (BR) following radical prostatectomy (RP) from a large consecutive cohort operated in an 18-year period. Additionally, an in-depth analysis of outcomes among D'Amico intermediate-risk patients is presented. <br> MATERIALS AND METHODS: A total of 2,091 patients with PCa who underwent RP at Department of Urology, Rigshospitalet, Copenhagen, Denmark between 1995 and 2013 were included. Univariate and multiple cause-specific Cox regression analyses for BR were applied using competing risk models. Death prior to BR was considered a competing event. BR was defined as the first PSA ≥0.2 ng/ml. No patient received adjuvant therapy prior to BR. <br> RESULTS: Overall, the 5- and 10-years cumulative incidence of BR was 21.9% and 32.0%. The 10-year cumulative incidence of BR was 17.9%, 31.9% and 47.9% for D'Amico low-, intermediate- and high-risk patients, respectively. Among intermediate-risk patients, the 10-year cumulative incidence of BR was 24.0%, 39.9%, and 47.9% for patients harboring one, two or three risk factors, respectively (Gray test: p < 0.0001). In multivariate analysis, PSA, RP GS, pT category, and positive surgical margins were significantly associated with an increased risk of BR. <br> CONCLUSIONS: The risk of BR among patients with intermediate-risk disease is not uniform and is highly dependent on the number of risk factors per patient. Intermediate-risk patients have a comparable risk of recurrence as high-risk patients, and this should be taken into consideration when counseling patients prior to RP.

Entities:  

Keywords:  D’Amico; Radical prostatectomy; biochemical recurrence; competing-risk; intermediate-risk

Mesh:

Substances:

Year:  2017        PMID: 28762283     DOI: 10.1080/21681805.2017.1356369

Source DB:  PubMed          Journal:  Scand J Urol        ISSN: 2168-1805            Impact factor:   1.612


  6 in total

1.  Smoking history, intensity, and duration and risk of prostate cancer recurrence among men with prostate cancer who received definitive treatment.

Authors:  Saira Khan; Shivani Thakkar; Bettina Drake
Journal:  Ann Epidemiol       Date:  2019-09-06       Impact factor: 3.797

2.  Secondary Treatment for Men with Localized Prostate Cancer: A Pooled Analysis of PRIAS and ERSPC-Rotterdam Data within the PIONEER Data Platform.

Authors:  Katharina Beyer; Vera Straten; Sebastiaan Remmers; Steven MacLennan; Sara MacLennan; Giorgio Gandaglia; Peter-Paul M Willemse; Ronald Herrera; Muhammad Imran Omar; Beth Russell; Johannes Huber; Markus Kreuz; Alex Asiimwe; Tom Abbott; Alberto Briganti; Mieke Van Hemelrijck; Monique J Roobol
Journal:  J Pers Med       Date:  2022-05-05

Review 3.  Radiomics in prostate cancer: an up-to-date review.

Authors:  Matteo Ferro; Ottavio de Cobelli; Gennaro Musi; Francesco Del Giudice; Giuseppe Carrieri; Gian Maria Busetto; Ugo Giovanni Falagario; Alessandro Sciarra; Martina Maggi; Felice Crocetto; Biagio Barone; Vincenzo Francesco Caputo; Michele Marchioni; Giuseppe Lucarelli; Ciro Imbimbo; Francesco Alessandro Mistretta; Stefano Luzzago; Mihai Dorin Vartolomei; Luigi Cormio; Riccardo Autorino; Octavian Sabin Tătaru
Journal:  Ther Adv Urol       Date:  2022-07-04

4.  Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.

Authors:  Lorenzo Tosco; Annouschka Laenen; Thomas Gevaert; Isabelle Salmon; Christine Decaestecker; Elai Davicioni; Christine Buerki; Frank Claessens; Johan Swinnen; Karolien Goffin; Raymond Oyen; Wouter Everaerts; Lisa Moris; Gert De Meerleer; Karin Haustermans; Steven Joniau
Journal:  BMC Cancer       Date:  2018-04-02       Impact factor: 4.430

5.  Predictors of Follow-Up Visits Post Radical Prostatectomy.

Authors:  Saira Khan; Veronica Hicks; Danielle Rancilio; Marvin Langston; Katina Richardson; Bettina F Drake
Journal:  Am J Mens Health       Date:  2018-03-14

6.  Blocking the Increase of Intracellular Deuterium Concentration Prevents the Expression of Cancer-Related Genes, Tumor Development, and Tumor Recurrence in Cancer Patients.

Authors:  Beáta Zs Kovács; László G Puskás; Lajos I Nagy; András Papp; Zoltán Gyöngyi; István Fórizs; György Czuppon; Ildikó Somlyai; Gábor Somlyai
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.